201 related articles for article (PubMed ID: 27400445)
1. The use of conformationally thermostabilised GPCRs in drug discovery: application to fragment, structure and biophysical techniques.
Tehan BG; Christopher JA
Curr Opin Pharmacol; 2016 Oct; 30():8-13. PubMed ID: 27400445
[TBL] [Abstract][Full Text] [Related]
2. Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile).
Christopher JA; Aves SJ; Bennett KA; Doré AS; Errey JC; Jazayeri A; Marshall FH; Okrasa K; Serrano-Vega MJ; Tehan BG; Wiggin GR; Congreve M
J Med Chem; 2015 Aug; 58(16):6653-64. PubMed ID: 26225459
[TBL] [Abstract][Full Text] [Related]
3. Structure-based and fragment-based GPCR drug discovery.
Andrews SP; Brown GA; Christopher JA
ChemMedChem; 2014 Feb; 9(2):256-75. PubMed ID: 24353016
[TBL] [Abstract][Full Text] [Related]
4. Potential for the Rational Design of Allosteric Modulators of Class C GPCRs.
Christopher JA; Doré AS; Tehan BG
Curr Top Med Chem; 2017; 17(1):71-78. PubMed ID: 27448651
[TBL] [Abstract][Full Text] [Related]
5. Integrated In Silico Fragment-Based Drug Design: Case Study with Allosteric Modulators on Metabotropic Glutamate Receptor 5.
Bian Y; Feng Z; Yang P; Xie XQ
AAPS J; 2017 Jul; 19(4):1235-1248. PubMed ID: 28560482
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in drug discovery of GPCR allosteric modulators for neurodegenerative disorders.
Lütjens R; Rocher JP
Curr Opin Pharmacol; 2017 Feb; 32():91-95. PubMed ID: 28135635
[TBL] [Abstract][Full Text] [Related]
7. Strategies for the identification of allosteric modulators of G-protein-coupled receptors.
Burford NT; Watson J; Bertekap R; Alt A
Biochem Pharmacol; 2011 Mar; 81(6):691-702. PubMed ID: 21184747
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 6-(pyrimidin-5-ylmethyl)quinoline-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5.
Felts AS; Rodriguez AL; Morrison RD; Blobaum AL; Byers FW; Daniels JS; Niswender CM; Conn PJ; Lindsley CW; Emmitte KA
Bioorg Med Chem Lett; 2018 Jun; 28(10):1679-1685. PubMed ID: 29705142
[TBL] [Abstract][Full Text] [Related]
9. Covalent allosteric modulation: An emerging strategy for GPCRs drug discovery.
Bian Y; Jun JJ; Cuyler J; Xie XQ
Eur J Med Chem; 2020 Nov; 206():112690. PubMed ID: 32818870
[TBL] [Abstract][Full Text] [Related]
10. Allosteric binding sites at the receptor-lipid bilayer interface: novel targets for GPCR drug discovery.
Wang Y; Yu Z; Xiao W; Lu S; Zhang J
Drug Discov Today; 2021 Mar; 26(3):690-703. PubMed ID: 33301977
[TBL] [Abstract][Full Text] [Related]
11. Structures of class B G protein-coupled receptors: prospects for drug discovery.
Hausch F
Angew Chem Int Ed Engl; 2013 Dec; 52(49):12783-5. PubMed ID: 24127232
[TBL] [Abstract][Full Text] [Related]
12. Fragment-based lead discovery on G-protein-coupled receptors.
Visegrády A; Keserű GM
Expert Opin Drug Discov; 2013 Jul; 8(7):811-20. PubMed ID: 23621346
[TBL] [Abstract][Full Text] [Related]
13. Current and Future Challenges in GPCR Drug Discovery.
Topiol S
Methods Mol Biol; 2018; 1705():1-21. PubMed ID: 29188556
[TBL] [Abstract][Full Text] [Related]
14. Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors.
Lindsley CW; Emmitte KA; Hopkins CR; Bridges TM; Gregory KJ; Niswender CM; Conn PJ
Chem Rev; 2016 Jun; 116(11):6707-41. PubMed ID: 26882314
[TBL] [Abstract][Full Text] [Related]
15. Clickable Photoaffinity Ligands for Metabotropic Glutamate Receptor 5 Based on Select Acetylenic Negative Allosteric Modulators.
Gregory KJ; Velagaleti R; Thal DM; Brady RM; Christopoulos A; Conn PJ; Lapinsky DJ
ACS Chem Biol; 2016 Jul; 11(7):1870-9. PubMed ID: 27115427
[TBL] [Abstract][Full Text] [Related]
16. Surface plasmon resonance analysis of seven-transmembrane receptors.
Aristotelous T; Hopkins AL; Navratilova I
Methods Enzymol; 2015; 556():499-525. PubMed ID: 25857797
[TBL] [Abstract][Full Text] [Related]
17. Insights into the interaction of negative allosteric modulators with the metabotropic glutamate receptor 5: discovery and computational modeling of a new series of ligands with nanomolar affinity.
Anighoro A; Graziani D; Bettinelli I; Cilia A; De Toma C; Longhi M; Mangiarotti F; Menegon S; Pirona L; Poggesi E; Riva C; Rastelli G
Bioorg Med Chem; 2015 Jul; 23(13):3040-58. PubMed ID: 26014480
[TBL] [Abstract][Full Text] [Related]
18. From purified GPCRs to drug discovery: the promise of protein-based methodologies.
Alkhalfioui F; Magnin T; Wagner R
Curr Opin Pharmacol; 2009 Oct; 9(5):629-35. PubMed ID: 19443270
[TBL] [Abstract][Full Text] [Related]
19. VU0477573: Partial Negative Allosteric Modulator of the Subtype 5 Metabotropic Glutamate Receptor with In Vivo Efficacy.
Nickols HH; Yuh JP; Gregory KJ; Morrison RD; Bates BS; Stauffer SR; Emmitte KA; Bubser M; Peng W; Nedelcovych MT; Thompson A; Lv X; Xiang Z; Daniels JS; Niswender CM; Lindsley CW; Jones CK; Conn PJ
J Pharmacol Exp Ther; 2016 Jan; 356(1):123-36. PubMed ID: 26503377
[TBL] [Abstract][Full Text] [Related]
20. The role of water and protein flexibility in the structure-based virtual screening of allosteric GPCR modulators: an mGlu
Orgován Z; Ferenczy GG; Keserű GM
J Comput Aided Mol Des; 2019 Sep; 33(9):787-797. PubMed ID: 31542869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
